PNNL

Dr. Douglas Mans is the Director of PNNL’s Environmental Molecular Sciences Division and the Environmental Molecular Sciences Laboratory (EMSL) user program. EMSL is a national scientific user facility sponsored by the U.S. Department of Energy's (DOE) Biological and Environmental Research (BER) program. Overseeing the EMSL user program, Mans is the primary interface with DOE BER and PNNL leadership. He works closely with the user community for science, management, and operations of EMSL. His scientific vision attracts outstanding staff scientists and users to EMSL facilities and programs, promotes innovative research, and fosters the creation of robust scientific teams and communities. He leads more than 160 staff members in growing EMSL's reputation as a premier scientific user facility. 

A biopharmaceutical strategic science and technology expert, Mans has more than 13 years of experience in the pharmaceutical industry. Before joining PNNL and EMSL in 2019, he was Innovation Director at Janssen Pharmaceuticals, managing a portfolio of global external innovation projects and collaborations starting in 2017. Mans spent most of his career at GlaxoSmithKline (GSK), a multinational pharmaceutical company. He started in 2006 as an investigator/principal scientist. He held several management positions of increasing responsibility at GSK, including Innovation Seeker, Global Director of Continuous Processing, Asset Management Lead, and Global Director for Chemical Catalysis and Novel Methods. In 2016, he was part of a team at ViiV Healthcare, a GSK subsidiary, developing innovative solutions to challenges associated with HIV treatments and patient support. 

Previous Research Interests 

• Total synthesis of natural and pharmaceutically active compounds 

• Accessing novel heterocyclic compounds via [3+2] azaallyl anion cycloadditions 

• Strategic and organizational constructs to foster integrative approaches to challenging problems and opportunities in the energy, environmental, and human health sectors

• Postdoctoral Fellow, National Institutes of Health, The University of Texas, 2006 

• PhD in Synthetic Organic Chemistry, University of Michigan, 2004 

• BA in Chemistry, St. Louis University, 1999 (summa cum laude) 

• American Chemical Society

• Two Exceptional Science Awards for Technical Expertise, GSK 

• Two Silver Impact Awards for Creative Contributions, GSK

• Three Bronze Impact Awards for Creative Contributions, GSK

• Goodman SN, MD Kowalski, DM Mans, W Huan. “Processes for preparing pyridinone carboxylic acid aldehydes.” US Patent 8,889,877. 

• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing carbamoylpyridone derivatives and intermediates.” US Patent App. 16/207,288. 

• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing pyridinone carboxylic acid derivatives and intermediates.” US Patent App. 16/207,243. 

• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing carbamoylpyridone derivatives and intermediates.” US Patent App. 16/207,273. 

• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing carbamoylpyridone derivatives and intermediates.” US Patent App. 15/907,683. 

• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing carbamoylpyridone derivatives and intermediates.” US Patent App. 15/907,626. 

• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing (4R, 12aS)-N-(2, 4-difluorobenzyl)-7-hydroxy-4-methyl-6, 8-dioxo-3, 4, 6, 8, 12, 12a-hexahydro-2H-pyrido [1', 2': 4, 5] pyrazino [2, 1-b][1, 3] oxazine.” US Patent 9,938,296. 

• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing (4R, 12aS)-N-(2, 4-difluorobenzyl)-7-methoxy-4-methyl-6, 8-dioxo-3, 4, 6, 8, 12, 12A-hexahydro-2H-pyrido [1', 2': 4, 5] pyrazino [2, 1-b][1, 3] oxazine. US Patent 9,643,981. 

• Goodman SN, W Huan, D Mans, M Kowalski. “Process for preparing (4R, 12aS)-7-methoxy-4-methyl-6, 8-dioxo-3, 4, 6, 8, 12, 12a-hexahydro-2H-pyrido [1', 2': 4, 5] pyrazino [2, 1-b][1, 3] oxazine-9-carboxylic acid.” US Patent 9,120,817. 

• Sisko J, D Mans, H Yin. “Process for preparing pyrano-[2, 3-C] pyridine derivatives.” US Patent 8,759,523.